Treatment of nightmare disorder Nervous System Diseases
Conditions
Interventions
Study I: Cross-cultural adaptation of psychometric instruments
Study II: Descriptive epidemiological study using quota sampling
Study III: Single-center interventional feasibility study (i.e., two g
several measures before, during and after treatment)
Nightmares are typically assessed in terms of their frequency, intensity, and distress. There are few validated instruments available in Portugues
Sponsors
Fundação para a Ciência e Tecnologia
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria for Study III will be as follows: 1. A diagnosis of ND based on the DSM-V-TR and ICSD-3, preferably with chronic nightmares, irrespective of the presence or absence of nocturnal awakenings 2. Minimum frequency: 1 nightmare/month.
Exclusion criteria
Exclusion criteria: 1. Exposure to significant and/or traumatic life events (e.g., pregnancy, death) in the last 6 months 2. Clinically significant symptoms of comorbid disorders incompatible with the implementation of the intervention program and/or study objectives (i.e., PTSD, Substance-related disorders, Psychotic Spectrum Disorders, Night Terrors, Sleepwalking, Narcolepsy, dissociation symptoms, severe depressive symptomatology and/or suicidal ideation), assessed by clinical interview and questionnaires) 3. Consumption/abstinence of medication/substances, which influence sleep architecture (e.g., alcohol) and/or the occurrence of nightmares 4. Psychological and/or psychiatric treatment in the last 6 months, particularly if directed to nightmares
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study III: Nightmare distress measured using the Nightmare Distress Questionnaire (NDQ) at baseline (T1) and the beginning of the first intervention session (pre-test-T2), in the middle of the intervention (during-T3), in the last intervention session (post-test-T4), and four weeks afterwards (Follow-up-T5) | — |
Secondary
| Measure | Time frame |
|---|---|
| Study III: Frequency, severity and intensity of nightmares, the degree of impairment in functioning, sleep quality and symptoms of insomnia measured through self-response questionnaires at baseline (T1) and the beginning of the first intervention session (pre-test-T2), in the middle of the intervention (during-T3), in the last intervention session (post-test-T4), and four weeks afterwards (Follow-up-T5) | — |
Countries
Portugal
Contacts
Public ContactFilipa;Ana Allen Almeida;Gomes
;
Outcome results
None listed